Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential intravenous and oral moxifloxacin versus comparator in pediatric complicated intraabdominal infection
2009-015578-37Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of moxifloxacin in Intra-abdominal infection (IAI) (2 arms), sponsored by Bayer. Primary endpoint: Overall safety. Started Dec 2009; status: completed.
02
Drugs
moxifloxacin
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2009-015578-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015578-37.